Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

The failure of Roche’s RG6206 marks another blow to the hypothesis that blocking myostatin can improve muscle growth and function in ambulatory boys with Duchenne muscular dystrophy.

Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy (PPMD), disclosing

Read the full 452 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE